Compare TG Therapeutics Inc (TGTX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Workiva Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Workiva Inc trades at $72.76 (market cap $4.01B). The key difference: TG Therapeutics Inc is far larger — about 2.1× Workiva Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | WK | |
|---|---|---|
Market Cap | $8.53B | $4.01B |
Sector | Health | Technology |
52-Week High | $59.06 | $93.31 |
52-Week Low | $26.94 | $44.31 |
Enterprise Value | $8.74B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Workiva (WK) trades at $73.71, down 3.71% today, showing technical support near $72 with bullish moving averages. The company demonstrates strong revenue growth, with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and high analyst buy ratings (89%) support optimism, though elevated valuation ratios (P/E 87.75) warrant caution.
Outlook remains positive with consistent earnings beats and AI product launches driving growth. Key risks include high valuation multiples and competitive pressures in the SaaS sector. The consensus price target of $82.50 suggests 12% upside potential from current levels, supported by institutional accumulation and strong operational cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
